Affirming support for most-favored-Nation drug pricing for United States patients.

[AI summary unavailable — showing source text] [Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H. Res. 928 Introduced in House (IH)] <DOC> 119th CONGRESS 1st Session H. RES. 928 Affirming support for most-favored-Nation drug pricing for United States patients. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES December 4, 2025 Mrs. Dingell (for herself and Mr. Crane) submitted the following resolution; which was referred to the Committee on Energy and Commerce _______________________________________________________________________ RESOLUTION Affirming support for most-favored-Nation drug pricing for United States patients. Whereas, according to a study conducted by the Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation and RAND Health Care in 2024, the United States spends a higher and growing share of total drug spending on new drugs compared to other countries; Whereas the United States prices across all drugs, both brand name and generic, were nearly 2.78 times as high as prices in the comparison countries; Whereas, on average, according to the Organization for Economic Cooperation …